$AVTX News

Citizens Maintains Market Outperform on Avalo Therapeutics, Lowers Price Target to $55

These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results

Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $34

Mizuho Maintains Outperform on Avalo Therapeutics, Raises Price Target to $45

HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $35

Avalo Therapeutics Q1 EPS $(0.98) Beats $(1.13) Estimate

Piper Sandler Maintains Overweight on Avalo Therapeutics, Raises Price Target to $60

Avalo Therapeutics: Abdakibart Delivers Breakout Phase 2 HS Data

Avalo Therapeutics Stock Soars After Positive LOTUS Trial Results

Citizens Maintains Market Outperform on Avalo Therapeutics, Raises Price Target to $62

Wedbush Maintains Outperform on Avalo Therapeutics, Raises Price Target to $40

BTIG Maintains Buy on Avalo Therapeutics, Raises Price Target to $58

Avalo Therapeutics Launches Common Stock, Pre-Funded Warrants Offering; Terms Undisclosed

Avalo Therapeutics Announces Topline Results From Phase 2 LOTUS Trial Evaluating Efficacy And Safety Of Abdakibart In Adults With Hidradenitis Suppurativa; LOTUS Trial Met Primary Endpoint At Both Doses Studied

BTIG Reiterates Buy on Avalo Therapeutics, Maintains $40 Price Target

Wolfe Research Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $48

Citizens Initiates Coverage On Avalo Therapeutics with Market Outperform Rating, Announces Price Target of $52

HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Raises Price Target to $40

BTIG Reiterates Buy on Avalo Therapeutics, Maintains $40 Price Target

Avalo Therapeutics Q4 EPS $(0.48) Beats $(1.47) Estimate, Sales $59.000K Down From $192.000K YoY